TYVASO DPI IS NOW APPROVED

Skip to main content

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Skip to main content

ADVERSE EVENT MANAGEMENT

Selected AE management approaches1-3*

Approaches to AE management are based on clinical expertise cited in an article on patients with PH-ILD by Lee et al1 and should not be construed as medical advice. United Therapeutics does not recommend or endorse using healthcare products other than as directed or prescribed.

Cough

Before treatment, eat a small amount of yogurt, honey, or peanut butter, or drink very cold or very warm water

Use a short-acting bronchodilator pretreatment

Review proper technique for the prescribed device

Temporary dose reductions and/or slower titration

OTC or prescription cough medicines

Consider adjusting or optimizing other airway medications

Headache

OTC pain relievers

Temporary dose reductions

Throat irritation

Oral analgesic spray

*AE management strategies should be dealt with in accordance with the TYVASO and TYVASO DPI Full Prescribing Information and your clinical judgment. 

 

AE=adverse event; OTC=over-the-counter.